Systemic sclerosis causes 1 in 2 deaths within 4 years of diagnosis

Key Concepts:

• Systemic Sclerosis (SSc): A chronic autoimmune disease causing hardening of the skin and affecting internal organs.
• Lung Fibrosis: Scarring of the lung tissue, a leading cause of death in SSc patients.
• Autoantibodies: Antibodies that attack the body's own tissues.
• Personalized Medicine: Tailoring medical treatment to the individual characteristics of each patient.
• AI (Artificial Intelligence): Used for integrating data and developing predictive algorithms.
• Singapore Systemic Sclerosis Position Medicine (SSc PosMed) project: A holistic research project integrating multiple dimensions of patient data.
• Asia-Pacific Region: The geographical area where the project's findings will be validated.

1. Introduction to the SSc PosMed Project

• A $6 million grant funds a new project at Singapore General Hospital (SGH) focusing on systemic sclerosis (SSc) patients.
• The project aims to improve diagnosis and personalize treatment for SSc.
• SSc has poor survival rates, with a significant number of Asian patients dying within 4 years of diagnosis.
• The project will study patients' genes, immune systems, and gut bacteria.

2. Understanding Systemic Sclerosis

• SSc, also known as scleroderma ("hard skin"), is caused by an immune system malfunction.
• The immune system attacks healthy tissue, leading to excessive collagen production.
• This results in skin hardening and restricted blood flow, particularly to the extremities.
• Internal organs such as the heart, muscles, joints, lungs, digestive system, and kidneys can also be affected.
• The exact cause of SSc remains unknown.
• There is currently no cure or fully effective treatment for SSc.
• The condition affects approximately 8 in 100,000 people, with around 550 patients in Singapore.
• Treatment focuses on managing symptoms, limiting organ damage, slowing disease progression, and improving quality of life.

3. Factors Contributing to Poor Survival Rates in Asian Patients

• Asians have a different autoantibody profile compared to Caucasians.
• The presence of the anti-centromere antibody (ACA) is more prevalent in Asians and is associated with increased risk of lung fibrosis.
• Lung fibrosis is a leading cause of death in SSc patients.
• Asian patients with lung fibrosis often present with more severe conditions.
• Genetic risk factors unique to East Asians (Chinese, Japanese, and Koreans) may also contribute to the different risk profile.

4. The Singapore Systemic Sclerosis Position Medicine (SSc PosMed) Project

• The SSc PosMed project differs from conventional approaches by taking a holistic approach.
• It integrates six different dimensions of patient data, including genetics, immunology, and microbiome.
• AI is used to integrate data and develop predictive algorithms to profile patients and predict outcomes.
• The project starts in Singapore but aims to apply to the rest of the Asia Pacific region due to its diversity.
• The second phase involves validating results across 16 centers in 7 countries in Asia.

5. Potential Benefits for Patients

• The research aims to develop personalized strategies for approaching the disease.
• This includes matching the right patients to the right drug at the right time.
• The goal is to treat patients in a timely manner without overtreatment.
• The project also aims to discover new drug targets to address the underlying causes of SSc.

6. The Path to a Cure and Future Steps

• While a complete cure within five years is considered unlikely, the project aims to identify new targets for drug development.
• The next step involves validating findings in the Asia-Pacific region.
• Novel lung cell imaging techniques are being explored to identify thresholds for predicting lung fibrosis progression.
• The project is engaging with industry partners to further develop potential treatments.

7. Notable Quotes

• Associate Professor Andrea Lo: "We know that Asians have a certain autoantibody profile different from people in the Caucasians and West... This particular icl 70 antibody is more prevalent in Asians and that it should come first increased miss off lung fibrosis."
• Associate Professor Andrea Lo: "This study differs from conventional approaches in that can better approaches, tends to focus on one aspect... But here we are actually looking at integrating 6 different dimensions of a patient... approaching in a very holistic way."
• Associate Professor Andrea Lo: "We're hoping to be able to have by the strategies to approach the disease. So, for example, matching the right patients to the right drug at the right time to very important to treat them in a very timely manner."

8. Technical Terms and Concepts

• Systemic Sclerosis (SSc): A chronic autoimmune disease affecting connective tissue.
• Lung Fibrosis: Scarring of the lung tissue, impairing its function.
• Autoantibodies: Antibodies that mistakenly target the body's own tissues.
• Personalized Medicine: Tailoring treatment to individual patient characteristics.
• AI (Artificial Intelligence): Used for data integration and predictive modeling.
• Microbiome: The community of microorganisms living in the gut.

9. Logical Connections

• The introduction establishes the problem of poor survival rates in Asian SSc patients.
• It then explains the underlying mechanisms of SSc and the factors contributing to the disparity in survival rates.
• The SSc PosMed project is presented as a novel approach to address these challenges through personalized medicine and AI.
• The discussion then shifts to the potential benefits for patients and the future steps needed to develop more effective treatments and potentially a cure.

10. Synthesis/Conclusion

The Singapore Systemic Sclerosis Position Medicine (SSc PosMed) project represents a significant effort to improve the diagnosis and treatment of systemic sclerosis, particularly in Asian patients who face poorer survival rates. By integrating multiple dimensions of patient data and leveraging AI, the project aims to develop personalized treatment strategies and identify new drug targets. While a complete cure remains a long-term goal, the project offers hope for more effective management of the disease and improved outcomes for patients in the Asia-Pacific region.